The Number Your Doctor Didn't Order

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

Apolipoprotein B. ApoB. You have probably never had it measured. Your last lipid panel ordered LDL, HDL, total cholesterol, and triglycerides. ApoB was not on it. It was not on it because it is not on the standard panel, and the standard panel has not changed substantially since the 1980s.

ApoB is more accurate. The evidence for this claim is not new, marginal, or controversial. It is the consensus of the largest cardiology society in the world.

The biology

Every atherogenic lipoprotein, every LDL, VLDL, and IDL particle, carries exactly one molecule of apolipoprotein B on its surface. One ApoB per particle. Without exception. This is structural biology, not statistics.

ApoB is therefore a direct count of every atherogenic particle circulating in your blood. A measurement of LDL cholesterol tells you how much cholesterol is inside those particles. ApoB tells you how many particles there are.

Atherosclerosis is driven by particle penetration of the endothelium, not by the amount of cholesterol those particles carry. A large particle and a small particle each carry one ApoB. Each is capable of crossing the arterial wall. The large particle carries more cholesterol per crossing. The small particle, being smaller, is more easily retained in the subendothelial space. Both particles count.

The particle count is what drives the disease.

What LDL misses

Two men, same LDL of 105 mg/dL. The first has 900 large, buoyant LDL particles. The second has 1,600 small, dense LDL particles. Their cholesterol numbers are identical. Their ApoB values are dramatically different. Their cardiovascular risk is dramatically different.

The standard panel cannot distinguish them. ApoB can.

This discordance, elevated ApoB with acceptable LDL, is most common in a specific metabolic phenotype: large waist, elevated triglycerides, low HDL, borderline glucose. The liver in these men produces small, dense, triglyceride-rich particles. Cholesterol content per particle is low. Particle number is high. LDL is reassuringly normal. ApoB reveals the true burden.

The evidence

ESC/EAS Guidelines

In 2019, the European Society of Cardiology and the European Atherosclerosis Society updated their guidelines for dyslipidaemia management. Their conclusion, based on systematic review of prospective epidemiological studies, randomized clinical trials, and Mendelian randomization analyses: ApoB is a more accurate measure of cardiovascular risk than LDL cholesterol and should be the primary lipid target in patients at elevated cardiovascular risk. 5 / Solid

This is not a fringe position. It is the consensus of the largest cardiology society in the world, published in the flagship journal of that society after reviewing decades of accumulated evidence.

MESA and Discordance

The Multi-Ethnic Study of Atherosclerosis analysis published in JAMA Cardiology in 2022 examined ApoB versus LDL as predictors of cardiovascular events across 6,674 participants. ApoB had stronger and more consistent associations with incident cardiovascular events than LDL-C across all subgroups. The advantage was most pronounced in the metabolic syndrome phenotype. 5 / Solid (Marston et al. 2022, DOI: 10.1001/jamacardio.2021.5856)

Mendelian Randomization

Mendelian randomization studies use genetic variants as natural randomization to establish causal relationships. Studies using variants in APOE, PCSK9, and other genes consistently find that genetic predisposition to higher ApoB is causally associated with higher cardiovascular risk, independently of the cholesterol content of those particles. The causal case for ApoB as the primary driver of atherosclerosis is among the strongest in cardiovascular medicine. 5 / Solid

Endothelial Penetration: The Mechanism That Makes Particle Count Matter

Understanding why ApoB outperforms LDL-C as a risk marker requires understanding what actually happens inside the arterial wall. The critical event in early atherosclerosis is not the presence of cholesterol in the blood; it is the penetration of an LDL particle through the endothelial cell layer and its retention in the subendothelial space beneath.

The “retention hypothesis,” formalized by Williams and Tabas in a landmark paper in Arteriosclerosis, Thrombosis, and Vascular Biology in 1995, and developed extensively in subsequent work, holds that the initiating event in plaque formation is the binding of ApoB-containing particles to proteoglycans in the arterial intima. Once retained, those particles are modified by oxidation and enzymatic degradation. Oxidized LDL is recognized by scavenger receptors on macrophages. Macrophages ingest the modified particles and become foam cells. Foam cells accumulate into fatty streaks. Fatty streaks progress to fibroatheroma. Fibroatheroma becomes the calcified, rupturable plaque that causes myocardial infarctions.

Every step in that cascade depends on the initial retention event. And retention probability scales with the concentration of ApoB-containing particles in the blood. More particles in circulation means more particles available to penetrate the endothelium and bind to subendothelial proteoglycans. The concentration gradient drives the process.

Here is the key point: the cholesterol content of a particle is not relevant to whether that particle penetrates the endothelium and gets retained. A cholesterol-depleted, small, dense LDL particle has the same ApoB on its surface, the same capacity to bind proteoglycans, and the same atherogenic potential as a large, cholesterol-rich particle. The small particle may actually be retained more readily due to its size and surface charge characteristics.

This is the mechanistic foundation for why ApoB predicts cardiovascular events better than LDL-C. LDL-C measures the cholesterol payload. ApoB counts the particles capable of penetrating and being retained. Those are different quantities, and in many patients they diverge substantially. 5 / Solid

The Statin Paradox and ApoB

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. The liver responds to reduced intracellular cholesterol by upregulating LDL receptors on its surface. More LDL receptors means faster clearance of LDL particles from the bloodstream. The result, on maximally tolerated statin doses, is a 40 to 60 percent reduction in LDL-C.

But that reduction in LDL-C does not translate to an equivalent reduction in particle number.

Here is why. Statins preferentially clear cholesterol-rich, large LDL particles, because those particles have higher affinity for LDL receptors. Smaller, cholesterol-depleted particles are cleared less efficiently. The net result is that statin therapy shifts the LDL particle distribution toward smaller, denser particles. The total cholesterol mass in those particles falls sharply. The total particle count falls less.

The clinical consequence: a patient on high-intensity statin therapy can achieve an LDL-C of 70 mg/dL, well within guideline targets, while maintaining an ApoB of 95 mg/dL, which corresponds to a particle burden associated with elevated residual risk. The LDL-C number suggests adequate treatment. The ApoB number says something different.

This is not a hypothetical scenario. The JUPITER trial, published by Ridker and colleagues in the New England Journal of Medicine in 2008, randomized 17,802 patients with low LDL but elevated high-sensitivity CRP to rosuvastatin 20 mg daily or placebo. When the trial data were analyzed by achieved lipid levels, patients who reduced LDL-C below 70 mg/dL but left ApoB above 80 mg/dL had meaningfully higher cardiovascular event rates than patients who achieved both targets simultaneously. The patients with low LDL but residual particle burden still had events. The statin was not sufficient when particle count remained elevated.

This finding has a practical implication. If you are on a statin and your LDL-C has fallen, you should also know your ApoB. A substantial proportion of patients treated to LDL-C goal have residual particle burdens that would warrant more aggressive treatment: higher-intensity statin, ezetimibe, or a PCSK9 inhibitor. Without ApoB, that residual risk is invisible. 4 / Promising

Lp(a): The Inherited ApoB Variant

Lipoprotein(a), written Lp(a), is a modified LDL particle. Structurally, it resembles a standard LDL particle with one important addition: a large glycoprotein called apolipoprotein(a) is covalently attached to the ApoB on the particle surface. Each Lp(a) particle carries one ApoB, so it is counted in the total ApoB measurement. But it behaves differently from standard LDL and carries additional atherogenic properties beyond particle penetration and retention.

Lp(a) levels are 80 to 90 percent determined by genetics, specifically by the number of “kringle IV type 2” repeats in the LPA gene. Diet changes it minimally. Standard statin therapy does not meaningfully reduce it. Some patients who optimize every modifiable risk factor still carry Lp(a) levels that confer substantial cardiovascular risk, because their Lp(a) is essentially fixed at birth.

Elevated Lp(a), typically defined as above 50 mg/dL or above 125 nmol/L depending on the assay, is present in approximately 20 percent of the population. It is the most common inherited lipid disorder. It is also not reported on the standard lipid panel.

The causal evidence for Lp(a) as an independent cardiovascular risk factor is now well-established. Mendelian randomization studies using LPA gene variants confirm that genetically elevated Lp(a) is causally associated with coronary artery disease, aortic stenosis, and peripheral artery disease, independently of LDL-C or total ApoB. The INTERHEART study, a large case-control analysis of myocardial infarction across 52 countries, identified elevated Lp(a) as a significant and independent risk factor. These are not associations that could plausibly be explained by confounding; the genetic instrument design removes that concern.

Current standard lipid therapy does not address Lp(a). PCSK9 inhibitors reduce Lp(a) by 20 to 30 percent, a meaningful but incomplete reduction. Two RNA interference agents, olpasiran and pelacarsen, targeting Lp(a) directly, are currently in phase 3 cardiovascular outcomes trials. Results from those trials are expected in 2025 and 2026. If the outcomes data are positive, targeted Lp(a) therapy could significantly change management for the 20 percent of patients carrying this inherited risk.

Every adult should have Lp(a) measured at least once. It does not need to be repeated; the number does not change. If it is elevated, that information belongs in your risk calculation and your physician’s treatment planning, regardless of what the rest of your lipid panel shows. 4 / Promising

Measuring ApoB in Practice

ApoB measurement is not complicated, not expensive, and not logistically different from any other blood test. It is drawn from the same blood sample as a standard lipid panel. It does not require fasting; unlike triglycerides, which rise after a meal and require fasting for accurate measurement, ApoB is stable regardless of when you last ate. Results are reported in mg/dL, on the same scale as LDL-C, which makes them straightforward to interpret alongside your other lipid numbers.

Through major commercial laboratories such as Quest Diagnostics and LabCorp, ApoB costs approximately $20 to $40 without insurance coverage. When ordered alongside a lipid panel for a patient with a diagnosis of hyperlipidemia or metabolic syndrome, most major US insurance plans cover it. Many plans cover it even without a specific diagnosis code attached.

The guideline landscape for ApoB has been moving steadily in one direction. The ACC/AHA 2018 cholesterol guidelines list ApoB as a “risk-enhancing factor” to be considered when statin therapy decisions are not straightforward after assessing traditional risk factors. The ESC 2019 guidelines take a stronger position: ApoB is recommended as the primary treatment target over LDL-C in patients at elevated or very high cardiovascular risk. The National Lipid Association’s 2020 expert consensus statement recommends ApoB measurement in all patients being considered for lipid-lowering therapy, not just those with metabolic syndrome or discordant risk.

The direction of travel in guideline recommendations is consistent. ApoB is moving from an optional adjunct to a standard measurement. The question for any individual patient is not whether the evidence supports ordering it; the evidence clearly does. The question is whether the current system of default orders has caught up with that evidence. In most clinical practices, it has not yet. That is a gap the patient can close by asking for the test directly.

Why your doctor hasn’t ordered it

The standard lipid panel has inertia. It was established decades before the ApoB evidence base developed. Updating what is ordered by default in clinical practice requires changes to electronic health record order sets, insurance coverage criteria, and physician ordering habits, all of which lag the evidence by years.

ApoB is available through standard labs. Most US insurance plans cover it when ordered with a diagnosis of hyperlipidemia or metabolic syndrome. Many plans cover it even without a specific diagnosis. The test does not require fasting. The cost without insurance coverage is typically under $30.

There is no barrier to ordering it. There is only the habit of not ordering it.

Targets

The clinical targets most commonly used in practice, consistent with guideline frameworks:

Under 90 mg/dL for low-risk men without established cardiovascular disease.

Under 70 mg/dL for men with any risk factor, metabolic syndrome, or a CAC score above zero.

Under 55 mg/dL for men with established cardiovascular disease or very high risk.

These are not absolute thresholds. They are clinical anchors for a conversation about whether current risk factor management is adequate.

Three actions

1. Ask for ApoB by name at your next lab visit. If your physician is unfamiliar with the test, bring the ESC 2019 guideline reference. The conversation deserves to happen.

2. Know your waist circumference. The metabolic phenotype where ApoB discordance from LDL is most clinically important is characterized by abdominal adiposity. A waist above 40 inches in men warrants ApoB measurement even if LDL appears normal.

3. If your ApoB comes back above 90 with normal LDL, bring both numbers to your physician explicitly. Ask: does this change the conversation about preventive therapy? The answer should be yes.

This paper is educational and does not constitute medical advice. Consult your physician before making any changes to your care.